State of the art in restless legs syndrome therapy: Practice recommendations for treating restless legs syndrome

Wolfgang H. Oertel, Claudia Trenkwalder, Marco Zucconi, Heike Benes, Diego Garcia Borreguero, Claudio Bassetti, Markku Partinen, Luigi Ferini-Strambi, Karin Stiasny-Kolster

Research output: Contribution to journalArticlepeer-review

Abstract

Dopaminergic agents are the best-studied agents and are considered first-line treatment of restless legs syndrome (RLS). Extensive data are available for levodopa, pramipexole, and ropinirole, which have approval for the indication RLS, and to a smaller extent for cabergolinc, pergolide, and rotigotine. Apart from one recent study, comparing two active drugs (levodopa and cabergolinc), no comparative studies have been published. The individual treatment regimen with the most appropriate agent concerning efficacy and side effects has to be selected by the treating physician. On the basis of these clinical trials and expert opinion of the authors, a treatment algorithm is proposed to support the search for the optimal individual treatment. Opioids and anticonvulsants such as gabapentine are second-line options in individual patients. Iron substitution is justified in people with iron deficiency related RLS (ferritin concentration lower than 50 μg/L).

Original languageEnglish
JournalMovement Disorders
Volume22
Issue numberSUPPL. 18
DOIs
Publication statusPublished - 2007

Keywords

  • Dopamine agonist
  • Levodopa
  • Opiod
  • RLS
  • Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'State of the art in restless legs syndrome therapy: Practice recommendations for treating restless legs syndrome'. Together they form a unique fingerprint.

Cite this